AIM ImmunoTech Inc. (AIM) Financial Ratios
30 years of historical data (1995–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
N/A
—
5yr avg: 98.12
30Y Low0.0·High196.5
ROE
↓
-388.7%
↑-214% vs avg
5yr avg: -123.9%
30Y Low-389%·High-21%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low1.7·High7.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AIM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
AIM ImmunoTech Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $31M | $1.1B | $2.0B | $1.4B | $4.1B | $5.4B | $185M | $748M | $944M | $1.4B | $1.8B |
| Enterprise Value | $33M | $1.1B | $2.0B | $1.4B | $4.1B | $5.3B | $190M | $754M | $945M | $1.4B | $1.8B |
| P/E Ratio → | -1.81 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 184.53 | 6201.40 | 9957.60 | 9940.00 | 30350.18 | 32897.71 | 1322.05 | 2038.95 | 2160.66 | 15394.20 | 13363.05 |
| P/B Ratio | — | — | 196.54 | 36.43 | 72.03 | 87.49 | 14.34 | 144.63 | 108.49 | 91.38 | 87.25 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
AIM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6208.69 | 9934.23 | 9754.07 | 30113.56 | 32675.53 | 1357.12 | 2054.28 | 2161.62 | 15368.02 | 13347.16 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
AIM Profitability
Margins and return-on-capital ratios measuring operating efficiency
AIM ImmunoTech Inc. earns an operating margin of -11630.6%. Operating margins have expanded from -14129.7% to -11630.6% over the past 3 years, signaling improving operational efficiency. A negative ROE of -388.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.8% | 81.8% | 79.2% | 400.7% | -529.6% | -394.5% | -537.9% | -140.9% | -170.7% | -1104.3% | -1101.5% |
| Operating Margin | -11630.6% | -11630.6% | -15800.0% | -14129.7% | -13954.1% | -9295.7% | -8887.9% | -3132.4% | -2612.4% | -15004.3% | -12518.8% |
| Net Profit Margin | -10188.2% | -10188.2% | -14337.6% | -13790.8% | -14168.1% | -8834.4% | -7732.9% | -2673.8% | -1889.9% | -8154.3% | -11451.1% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -388.7% | -388.7% | -118.9% | -40.8% | -32.4% | -38.8% | -119.8% | -141.4% | -68.3% | -41.8% | -67.1% |
| ROA | -123.8% | -123.8% | -96.8% | -39.6% | -22.7% | -21.9% | -63.6% | -70.0% | -49.9% | -36.0% | -58.3% |
| ROIC | -546.1% | -546.1% | -269.5% | -80.4% | -56.5% | -53.0% | -65.2% | -86.5% | -77.1% | -66.1% | -60.7% |
| ROCE | -403.4% | -403.4% | -128.0% | -41.4% | -22.6% | -23.5% | -90.0% | -114.7% | -81.7% | -75.0% | -73.4% |
AIM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $1M ($3M total debt minus $2M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.07 | 0.02 | 0.00 | 0.04 | 0.49 | 1.15 | 0.21 | — | 0.00 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.46 | -0.68 | -0.56 | -0.59 | 0.38 | 1.09 | 0.05 | -0.16 | -0.10 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -33.80 | -33.80 | — | — | -281.16 | -22.55 | -29.14 | -22.90 | -82.13 | — | -5550.00 |
AIM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.44x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 26.69x to 0.44x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.44 | 0.44 | 1.68 | 26.69 | 74.61 | 36.58 | 9.27 | 0.72 | 1.29 | 2.85 | 4.34 |
| Quick Ratio | 0.44 | 0.44 | 1.72 | 26.69 | 74.61 | 36.58 | 9.27 | 0.72 | 1.29 | 2.85 | 3.80 |
| Cash Ratio | 0.42 | 0.42 | 1.51 | 25.12 | 71.72 | 35.39 | 7.79 | 0.34 | 0.78 | 2.41 | 3.66 |
| Asset Turnover | — | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | 0.03 | 0.00 | 0.01 |
| Inventory Turnover | 1.21 | — | — | — | — | — | — | — | — | — | 1.21 |
| Days Sales Outstanding | — | — | 2139.41 | 4338.58 | 4436.78 | 2516.93 | 2137.86 | 1088.04 | 20.05 | — | — |
AIM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
AIM ImmunoTech Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $56M | $49M | $48M | $47M | $32M | $4M | $1M | $651721 | $495862 | $447251 |
Peer Comparison
Compare AIM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AIMYou | $31M | -1.8 | — | — | 81.8% | -11630.6% | -388.7% | -546.1% | — |
 IMMP | $64M | -1.4 | — | — | -1117.6% | -2506.5% | -36.9% | -176.9% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 IOVA | $1B | -3.3 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 INO | $642M | -0.8 | — | — | — | — | -703.1% | — | — |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 ADMA | $2B | 14.1 | 10.1 | 73.1 | 57.4% | 37.5% | 35.6% | 36.0% | 0.4 |
 VXRT | $178M | 10.6 | 7.4 | 23.5 | — | 7.6% | 22.3% | 27.1% | 0.5 |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 MRK | $277B | 15.4 | 10.7 | 22.4 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See AIM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AIM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AIM vs IMMP
Side-by-side business, growth, and profitability comparison vs Immutep Limited.
Start ComparisonAIM — Frequently Asked Questions
Quick answers to the most common questions about buying AIM stock.
What is AIM ImmunoTech Inc.'s P/E ratio?
AIM ImmunoTech Inc.'s current P/E ratio is -1.8x. This places it at the 50th percentile of its historical range.
What is AIM ImmunoTech Inc.'s ROE?
AIM ImmunoTech Inc.'s return on equity (ROE) is -388.7%. The historical average is -85.0%.
Is AIM stock overvalued?
Based on historical data, AIM ImmunoTech Inc. is trading at a P/E of -1.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are AIM ImmunoTech Inc.'s profit margins?
AIM ImmunoTech Inc. has 81.8% gross margin and -11630.6% operating margin.